ALNY vs MRNA
Alnylam Pharmaceuticals, Inc. and Moderna, both Healthcare
Alnylam Pharmaceuticals, Inc. is the larger company at $39B against $25B. Over the past year MRNA returned +93% against -49% for ALNY. The RyuScore puts MRNA ahead, 48 against 15 out of 100.
| Figure | ALNY | MRNA |
|---|---|---|
| Last close | $233 | $62.96 |
| Market cap | $39B | $25B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 118.1 | n/a |
| 1-year return | -49% | +93% |
| 5-year return | +24% | -81% |
| RyuScoresector-relative, 1–10 | 15/100 | 48/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Alnylam Pharmaceuticals, Inc.
Revenue of $2.5B in H1 2026, net income $370M. Its largest reported line is Amvuttra, 67% of the disclosed total.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.